Brief: Gossamer Bio And Chiesi Group Announce Transformative Global Collaboration To Develop And Commercialize Seralutinib In PAH, PH-ILD & Other Indications

Gossamer Bio

06/05/2024 12:32

May 6 (Reuters) - Gossamer Bio Inc  GOSS.O :
    * GOSSAMER BIO AND CHIESI GROUP ANNOUNCE TRANSFORMATIVE
GLOBAL
COLLABORATION TO DEVELOP AND COMMERCIALIZE SERALUTINIB IN PAH,
PH-ILD & OTHER INDICATIONS
    * GOSSAMER BIO INC: GOSSAMER TO RECEIVE $160 MILLION
DEVELOPMENT
REIMBURSEMENT PAYMENT
    * GOSSAMER BIO INC: ELIGIBLE TO RECEIVE UP TO $146 MILLION
IN
REGULATORY AND $180 MILLION IN SALES MILESTONES
    * GOSSAMER BIO INC: GOSSAMER AND CHIESI PLAN TO INITIATE
PHASE 3
TRIAL OF SERALUTINIB IN PH-ILD IN MID-2025
    * GOSSAMER BIO INC: WILL CONTINUE TO LEAD GLOBAL DEVELOPMENT
OF
SERALUTINIB IN PAH AND PH-ILD
    * GOSSAMER BIO INC: IN US, COMPANIES WILL EVENLY SHARE
COMMERCIAL
PROFITS AND LOSSES
    * GOSSAMER BIO INC: CHIESI WILL HAVE EXCLUSIVE RIGHT TO
COMMERCIALIZE SERALUTINIB OUTSIDE OF US

Source text for Eikon:  ID:nBw6FYz7Ca 
Further company coverage:  GOSS.O 

 ((Reuters.Briefs@thomsonreuters.com;))